The Ministry of Health of the Russian Federation has granted a permit to the Chumakov Center for clinical trials of CoviVak coronavirus vaccine in people over 60 years of age. This is evidenced by the data stored in the State Register of permits for drugs trials.
According to the State Register, the permit was issued on October 8. It is planned that the trial will end on August 1, 2022.
250 volunteers will take part in the tests. They will be held in three medical centers: Mechnikov Research Institute of Vaccines and Serums (Moscow), Perm State Medical University named after Academician E. A. Wagner and the medical and primary healthcare unit of the FMBA No. 163 (Koltsovo, Novosibirsk Region).
In June, the Chumakov Center began phase 3 of clinical trials of CoviVak with the participation of more than 30,000 volunteers.
Nanolek announced that it starts CoviVac production in November.
